Refractory Nasopharyngeal Carcinoma: Positron Emission Tomography Combined with Computed Tomography–Guided <sup>125</sup>I Seed Implantation Therapy after Repeated Traditional Radiochemotherapy

Zhang, Fujun; Wu, Ke; Gao, Fei; Zhang, Weidong; Shi, Feng; Li, Chuanxing

doi:10.1177/0194599813491221

Cited by 6 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The definition of refractory NPC is not consistent across studies. Zhang et al [16] defined patients with refractory NPC as those who had recurrence tumors but cannot tolerate surgical removal or reirradiation and chemotherapy after adequate doses of radiotherapy. Gao et al, [17] in contrast, defined NPC that did not respond to previous chemotherapy regimens as refractory.…”

Section: Discussionmentioning

confidence: 99%

Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma

Chen

Liu²,

Zhou³

et al. 2019

Medicine

View full text Add to dashboard Cite

Rationale: Refractory nasopharyngeal carcinoma is challenging to treat and at present there is no standard treatment or any good choice. Patient concerns: Although the three patients in our case reports had already underwent multiple treatments before, they still suffered from disease recurrence of nasopharyngeal carcinoma. Diagnosis: They were diagnosed as refractory nasopharyngeal carcinoma. Interventions: A continuous infusion of Endostar, an antiangiogenic agent, combined with chemotherapy and radiation therapy was given to treat the patients. Outcomes: Patients showed complete or partial response to the combined therapy as evidenced by regression of tumors and decrease in plasma Epstein–Barr virus (EBV) DNA load. Lessons: Continuous infusions of Endostar in combination with chemotherapy and/or radiation therapy showed promising efficacy and safety. The combination therapy indicates a new approach to treat refractory nasopharyngeal carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma

Chen

Liu²,

Zhou³

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

“…Implantation of 125 I radioactive seeds into NPC tumor tissues, under the guidance of positron emission tomography combined with computed tomography (PET-CT), proved to be an acceptable and feasible treatment with minimal damage and few complications in refractory NPC [ 30 ]. 131 I has a half-life of 8 days, and expends 971 KeV of decay energy with gamma decay following rapidly after beta decay, which is more powerful than 125 I.…”

Section: Discussionmentioning

confidence: 99%

In vivo Molecular Imaging and Radionuclide (131I) Therapy of Human Nasopharyngeal Carcinoma Cells Transfected with a Lentivirus Expressing Sodium Iodide Symporter

et al. 2015

View full text Add to dashboard Cite

IntroductionDespite recent improvements in the survival rates for nasopharyngeal carcinoma (NPC), novel treatment strategies are required to improve distant metastasis-free survival. The sodium iodine symporter (NIS) gene has been applied for in vivo imaging and cancer therapy. In this study, we examined the potential of NIS gene therapy as a therapeutic approach in NPC by performing non-invasive imaging using 125I and 131I therapy in vivo.MethodsWe constructed a lentiviral vector expressing NIS and enhanced green fluorescent protein (EGFP) under the control of the human elongation factor-1α (EF1α) promoter, and stably transfected the vector into CNE-2Z NPC cells to create CNE-2Z-NIS cells. CNE-2Z and CNE-2Z-NIS tumor xenografts were established in nude mice; 125I uptake, accumulation and efflux were measured using micro-SPECT/CT imaging; the therapeutic effects of treatment with 131I were assessed over 25 days by measuring tumor volume and immunohistochemical staining of the excised tumors.ResultsqPCR, immunofluorescence and Western blotting confirmed that CNE-2Z-NIS cells expressed high levels of NIS mRNA and protein. CNE-2Z-NIS cells and xenografts took up and accumulated significantly more 125I than CNE-2Z cells and xenografts. In vitro, 131I significantly reduced the clonogenic survival of CNE-2Z-NIS cells. In vivo, 131I effectively inhibited the growth of CNE-2Z-NIS xenografts. At the end of 131I therapy, CNE-2Z-NIS xenograft tumor cells expressed higher levels of NIS and caspase-3 and lower levels of Ki-67.ConclusionLentiviruses effectively delivered and mediated long-lasting expression of NIS in CNE-2Z cells which enabled uptake and accumulation of radioisotopes and provided a significant therapeutic effect in an in vivo model of NPC. NIS-mediated radioiodine treatment merits further investigation as a potentially effective, low toxicity therapeutic strategy for NPC.

show abstract

“…The dose was prescribed as the minimum peripheral dose (MPD), which included the PTV. The median MPD was 130 Gy (range 90–160 Gy) 23 . The distribution and MPD of 125 I seeds were calculated by using a computer processing planning system (RT-RSI, Beijing Atom and High Technique Industries Inc., Beijing, China) 24 .…”

Section: Methodsmentioning

confidence: 99%

Therapeutic effects and prognostic factors of 125I brachytherapy for pelvic recurrence after early cervical cancer surgery

Wang

Zhu

Yang

et al. 2021

Sci Rep

View full text Add to dashboard Cite

To investigate the efficacy of 125I seed implantation in the treatment regimen of pelvic recurrence after early cervical cancer surgery and to analyse prognostic factors. To evaluate efficacy and analyse prognostic factors of 125I seed implantation for pelvic recurrence after early cervical cancer surgery. A prospective study was conducted on 62 patients who experienced pelvic recurrence after early cervical cancer surgery between August 2005 and September 2015. The 62 patients were treated and assessed in 2 groups (n = 30). All 62 patients were randomized into two groups that received two different treatment regimens: the treatment group (n = 30), which received 125I particle implantation therapy, and the control group (n = 32), which received whole-pelvic irradiation using the anteroposterior/posteroanterior field and cisplatin-based concurrent chemoradiation therapy. The efficacy/efficiency of 125I seed implantation and prognostic factors were analysed by logistic regression. Overall survival was determined by Kaplan–Meier analysis. Multivariate analysis results were obtained by the Cox proportional hazards regression model. The effective control rates at 1, 3, 6 and 12 months were 76.7%, 80.0%, 83.3%, and 86.7% in the 125I particle implantation group. The total effective control rates at 1, 3, 6 and 12 months were 65.6%, 65.5%, 62.5%, and 71.9% in the chemoradiotherapy group. Significant differences were observed between the two groups. The overall survival rates at 1, 2, 3, 4, and 5 years and the median overall were 96.7%, 93.3%, 86.7%, 71.9%, 65.6% and 4.34 years, respectively, in the 125I seed implantation group and 81.3%, 71.9%, 62.5%, 56.3%, 53.1% and 3.59 years, respectively, in the control group. There were statistically significant differences in survival rates depending on the diameter of the largest recurrent pelvic tumour (χ2 = 6.611, P = 0.010). The multivariate analysis showed that the survival rates were related to the diameter of the largest recurrent pelvic tumour (χ2 = 4.538, P = 0.033). 125I implantation is an effective, safe, and promising method for the treatment of pelvic recurrence after early cervical cancer surgery. The diameter of the recurrent pelvic tumour was identified as a significant independent prognostic factor in patients who received 125I implantation.

show abstract

Refractory Nasopharyngeal Carcinoma: Positron Emission Tomography Combined with Computed Tomography–Guided ¹²⁵I Seed Implantation Therapy after Repeated Traditional Radiochemotherapy

Abstract: PET-CT-guided (125)I seed implantation is an acceptable and feasible method for treating refractory nasopharyngeal carcinoma with minimal damage and few complications.

Cited by 6 publications

References 37 publications

Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma

Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma

In vivo Molecular Imaging and Radionuclide (131I) Therapy of Human Nasopharyngeal Carcinoma Cells Transfected with a Lentivirus Expressing Sodium Iodide Symporter

Therapeutic effects and prognostic factors of 125I brachytherapy for pelvic recurrence after early cervical cancer surgery

Contact Info

Product

Resources

About

Refractory Nasopharyngeal Carcinoma: Positron Emission Tomography Combined with Computed Tomography–Guided 125I Seed Implantation Therapy after Repeated Traditional Radiochemotherapy

Abstract: PET-CT-guided (125)I seed implantation is an acceptable and feasible method for treating refractory nasopharyngeal carcinoma with minimal damage and few complications.

Cited by 6 publications

References 37 publications

Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma

Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma

In vivo Molecular Imaging and Radionuclide (131I) Therapy of Human Nasopharyngeal Carcinoma Cells Transfected with a Lentivirus Expressing Sodium Iodide Symporter

Therapeutic effects and prognostic factors of 125I brachytherapy for pelvic recurrence after early cervical cancer surgery

Contact Info

Product

Resources

About

Refractory Nasopharyngeal Carcinoma: Positron Emission Tomography Combined with Computed Tomography–Guided ¹²⁵I Seed Implantation Therapy after Repeated Traditional Radiochemotherapy